F-star Therapeutics, Inc. FSTX
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 156.51M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.07
- Beta
- -0.35
- Short ratio
- 2.59
- Inst. own
- 44.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 13, 2023
- 50-d avg
- 5.63
- 200-d avg
- 5.74
- 1y target
- 7.00
News
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
3 years ago seekingalpha.com
F-star's Delayed Acquisition Presents A Risky Opportunity
FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
-
4 years ago benzinga.com
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per…
4 years ago seekingalpha.com
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
4 years ago zacks.com
New Strong Buy Stocks for July 15th
GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
4 years ago zacks.com
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
4 years ago benzinga.com
F-star Therapeutics Shares Are Rallying Today - Read Why
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at…
4 years ago zacks.com
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the…
-
4 years ago benzinga.com
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
4 years ago zacks.com
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
4 years ago seekingalpha.com
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
4 years ago globenewswire.com
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows.
4 years ago globenewswire.com
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next…
4 years ago seekingalpha.com
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
The company's unique selling proposition is its novel, tetravalent bispecific antibody platform which has earned validation through partnership deals with big pharma like Merck.
4 years ago globenewswire.com
F-star Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing…
4 years ago globenewswire.com
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody Expands into Tumor Specific Indications First-in-Human Study of Company's CD137/PD-L1 Tetravalent Bispecific Antibody…
4 years ago zacks.com
F-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
F-star Therapeutics (FSTX) has been struggling lately, but the selling pressure may be coming to an end soon.
4 years ago seekingalpha.com
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q3 2021 Results - Earnings Call Transcript
4 years ago globenewswire.com
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
Dr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific
-
4 years ago benzinga.com
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
5 years ago globenewswire.com
F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next…
5 years ago seekingalpha.com
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q2 2021 Results - Earnings Call Transcript
F-star Therapeutics, Inc. (FSTX) CEO Eliot Forster on Q2 2021 Results - Earnings Call Transcript
-
5 years ago benzinga.com
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
5 years ago zacks.com
Why F-star Therapeutics (FSTX) Might Surprise This Earnings Season
F-star Therapeutics (FSTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 years ago zacks.com
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows.
-
5 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021
Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021